Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
04 Dec 2023
04 Dec 2023
Historique:
medline:
18
12
2023
pubmed:
18
12
2023
entrez:
18
12
2023
Statut:
epublish
Résumé
Anti-CD38 antibody therapies have transformed multiple myeloma (MM) treatment. However, a large fraction of patients inevitably relapses. To understand this, we investigated 32 relapsed MM patients treated with daratumumab, lenalidomide, and dexamethasone (Dara-Rd; NCT03848676 ). Whole genome sequencing (WGS) before and after treatment pinpointed genomic drivers associated with early progression, including
Identifiants
pubmed: 38106151
doi: 10.1101/2023.12.04.23299287
pmc: PMC10723485
pii:
doi:
Types de publication
Preprint
Langues
eng